Esophageal cancer is cancer that occurs in the
esophagus. Symptoms include cough, difficulty swallowing, chest pain,
pressure or burning and weight loss. Predisposing factors include age,
smoking, obesity and bile reflux. Treatment includes chemotherapy,
radiation therapy and surgery.
Report Highlights
Pharmaceutical
and Healthcare latest pipeline guide Esophageal Cancer - Pipeline
Review, H1 2017, provides comprehensive information on the therapeutics
under development for Esophageal Cancer (Oncology), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press
releases.
Browse Detail Report With TOC @ http://www.hexareports.com/report/esophageal-cancer-pipeline-review-h1-2017
The
Esophageal Cancer (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Esophageal Cancer and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1
respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules,
respectively.
Esophageal Cancer (Oncology) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is
built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
Request A Sample copy of This Report @ http://www.hexareports.com/report/esophageal-cancer-pipeline-review-h1-2017/request-sample
Note:
Certain content / sections in the pipeline guide may be removed or
altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The
pipeline guide reviews pipeline therapeutics for Esophageal Cancer
(Oncology) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- The
pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
- The pipeline guide features descriptive drug profiles
for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA
& other developmental activities.
- The pipeline guide reviews
key companies involved in Esophageal Cancer (Oncology) therapeutics and
enlists all their major and minor projects.
- The pipeline guide
evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism
of action (MoA), drug target, route of administration (RoA) and molecule
type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
Reasons To Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize
emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate
corrective measures for pipeline projects by understanding Esophageal
Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop
and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and
expand business potential and scope.
- Adjust the therapeutic
portfolio by recognizing discontinued projects and understand from the
know-how what drove them from pipeline.
Browse More Pharmaceuticals & Healthcare Related Market Research Reports:
- Gouty Arthritis (Gout) - Pipeline Review, H1 2017 -
http://www.hexareports.com/report/gouty-arthritis-gout-pipeline-review-h1-2017
- Osteonecrosis - Pipeline Review, H1 2017 -
http://www.hexareports.com/report/osteonecrosis-pipeline-review-h1-2017
- Type 2 Diabetes - Pipeline Review, H1 2017 -
http://www.hexareports.com/report/type-2-diabetes-pipeline-review-h1-2017
